HUE057455T2 - Spiroheptán szalicilamidok és rokon vegyületek mint ROCK inhibitorok - Google Patents

Spiroheptán szalicilamidok és rokon vegyületek mint ROCK inhibitorok

Info

Publication number
HUE057455T2
HUE057455T2 HUE17701785A HUE17701785A HUE057455T2 HU E057455 T2 HUE057455 T2 HU E057455T2 HU E17701785 A HUE17701785 A HU E17701785A HU E17701785 A HUE17701785 A HU E17701785A HU E057455 T2 HUE057455 T2 HU E057455T2
Authority
HU
Hungary
Prior art keywords
related compounds
rock inhibitors
salicylamides
spiroheptane
spiroheptane salicylamides
Prior art date
Application number
HUE17701785A
Other languages
English (en)
Hungarian (hu)
Inventor
Ii Leon M Smith
Vladimir Ladziata
Indawati Delucca
Donald Pinto
Michael J Orwat
Andrew K Dilger
Kumar Balashanmuga Pabbisetty
Wu Yang
Scott A Shaw
Peter W Glunz
Manoranjan Panda
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of HUE057455T2 publication Critical patent/HUE057455T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
HUE17701785A 2016-01-13 2017-01-13 Spiroheptán szalicilamidok és rokon vegyületek mint ROCK inhibitorok HUE057455T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662278122P 2016-01-13 2016-01-13

Publications (1)

Publication Number Publication Date
HUE057455T2 true HUE057455T2 (hu) 2022-05-28

Family

ID=57907009

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE17701785A HUE057455T2 (hu) 2016-01-13 2017-01-13 Spiroheptán szalicilamidok és rokon vegyületek mint ROCK inhibitorok

Country Status (29)

Country Link
US (2) US10611776B2 (enExample)
EP (2) EP3402790B1 (enExample)
JP (2) JP6976953B2 (enExample)
KR (1) KR102725741B1 (enExample)
CN (1) CN108699038B (enExample)
AR (1) AR107354A1 (enExample)
AU (2) AU2017206820B2 (enExample)
BR (1) BR112018013780B1 (enExample)
CA (1) CA3010900A1 (enExample)
CL (1) CL2018001899A1 (enExample)
CO (1) CO2018008173A2 (enExample)
CY (1) CY1124858T1 (enExample)
EA (1) EA036172B1 (enExample)
ES (1) ES2898698T3 (enExample)
HR (1) HRP20211888T1 (enExample)
HU (1) HUE057455T2 (enExample)
IL (1) IL260448B (enExample)
LT (1) LT3402790T (enExample)
MA (2) MA55633A (enExample)
MX (2) MX382434B (enExample)
PL (1) PL3402790T3 (enExample)
PT (1) PT3402790T (enExample)
RS (1) RS62690B1 (enExample)
SG (1) SG11201805927YA (enExample)
SI (1) SI3402790T1 (enExample)
SM (1) SMT202100660T1 (enExample)
TW (1) TWI730032B (enExample)
UY (1) UY37073A (enExample)
WO (1) WO2017123860A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201630899A (zh) 2015-01-09 2016-09-01 必治妥美雅史谷比公司 作為ｒｏｃｋ抑制劑的環狀脲類
ES2730112T3 (es) 2015-03-09 2019-11-08 Bristol Myers Squibb Co Lactamas como inhibidores de ROCK
JP6917379B2 (ja) 2016-01-13 2021-08-11 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング ８−アミノ−２−オキソ−１，３−ジアザ−スピロ−［４．５］−デカン誘導体
RS60224B1 (sr) 2016-01-13 2020-06-30 Gruenenthal Gmbh Derivati 3-(karboksimetil)-8-amino-2-okso-1,3-diaza-spiro-[4.5]-dekana
HRP20250176T1 (hr) 2016-01-13 2025-04-11 Grünenthal GmbH Derivati 3-((hetero-)aril)-8-amino-2-okso-1,3-diaza-spiro-[4.5]-dekana
UY37073A (es) * 2016-01-13 2017-07-31 Bristol-Myers Squibb Company Una Corporación Del Estado De Delaware Salicilamidas espiroheptanos y compuestos relacionados como inhibidores de rock, y las composiciones que los contienen
AR107360A1 (es) 2016-01-13 2018-04-25 Gruenenthal Gmbh Derivados de 3-((hetero)aril)-alquil-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
CN114539284A (zh) 2016-03-16 2022-05-27 库拉肿瘤学公司 经取代的menin-mll抑制剂及使用方法
US10562887B2 (en) 2016-05-27 2020-02-18 Bristol-Myers Squibb Company Triazolones and tetrazolones as inhibitors of ROCK
JP7155102B2 (ja) 2016-07-07 2022-10-18 ブリストル－マイヤーズ スクイブ カンパニー Ｒｏｃｋ阻害剤としてのスピロ縮合環尿素
WO2018009625A1 (en) 2016-07-07 2018-01-11 Bristol-Myers Squibb Company Spirolactams as inhibitors of rock
WO2018009622A1 (en) 2016-07-07 2018-01-11 Bristol-Myers Squibb Company Lactam, cyclic urea and carbamate, and triazolone derivatives as potent and selective rock inhibitors
KR102511441B1 (ko) 2016-11-30 2023-03-16 브리스톨-마이어스 스큅 컴퍼니 트리시클릭 Rho 키나제 억제제
US12060341B2 (en) 2017-07-12 2024-08-13 Bristol-Myers Squibb Company Spiroheptanyl hydantoins as ROCK inhibitors
CN110869361B (zh) * 2017-07-12 2023-06-02 百时美施贵宝公司 用于治疗心力衰竭的rock的五元氨基杂环和5,6元或6,6元双环氨基杂环抑制剂
ES2878054T3 (es) * 2017-07-12 2021-11-18 Bristol Myers Squibb Co Espiroheptanil hidantoínas como inhibidores de ROCK
TW201908293A (zh) * 2017-07-12 2019-03-01 美商必治妥美雅史谷比公司 作為rock抑制劑之5員及雙環雜環醯胺
US11306081B2 (en) 2017-07-12 2022-04-19 Bristol-Myers Squibb Company Phenylacetamides as inhibitors of rock
WO2019060365A1 (en) 2017-09-20 2019-03-28 Kura Oncology, Inc. SUBSTITUTED MÉNINE-MLL INHIBITORS AND METHODS OF USE
WO2019089868A1 (en) 2017-11-03 2019-05-09 Bristol-Myers Squibb Company Diazaspiro rock inhibitors
CN112313208B (zh) * 2018-04-17 2024-04-19 泰普斯特医疗公司 双环羧酰胺及其使用方法
KR20240110954A (ko) 2021-11-11 2024-07-16 학교법인 도시샤 각막 내피 세포의 냉동보존 제제 및 상기 냉동보존 제제를 생산하기 위한 방법
JP2023120893A (ja) 2022-02-18 2023-08-30 キヤノン株式会社 保持装置、リソグラフィ装置、および物品製造方法
EP4554931A1 (en) * 2022-07-12 2025-05-21 Adama Makhteshim Ltd. Process for preparing substituted benzamides
WO2024229439A2 (en) * 2023-05-03 2024-11-07 The University Of Chicago Inhibitors of nsun1- and nsun2-mediated active structures
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025247783A1 (en) 2024-05-29 2025-12-04 Syngenta Crop Protection Ag Pesticidally active dihydro-benzoxazinone compounds
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090026264A (ko) * 2006-06-08 2009-03-12 우베 고산 가부시키가이샤 측쇄에 스피로 고리 구조를 갖는 신규 인다졸 유도체
JP5235887B2 (ja) 2006-09-20 2013-07-10 アエリー ファーマシューティカルズ インコーポレイテッド Ｒｈｏキナーゼ阻害剤
ES2625266T3 (es) * 2006-12-27 2017-07-19 Sanofi Derivados de isoquinolona sustituidos con cicloalquilamina
CL2007003874A1 (es) 2007-01-03 2008-05-16 Boehringer Ingelheim Int Compuestos derivados de benzamida; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades cardiovasculares, hipertension, aterosclerosis, reestenosis, ictus, insuficiencia cardiaca, lesion isquemica, hipertensio
JP2011507921A (ja) * 2007-12-26 2011-03-10 サノフィ−アベンティス ６−置換−１−（２ｈ）−イソキノリノンの製造法
AR083855A1 (es) 2010-11-15 2013-03-27 Abbott Lab Inhibidores de nampt y rock
JP6488239B2 (ja) 2013-01-18 2019-03-20 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｒｏｃｋ阻害剤としてのフタラジノンおよびイソキノリノン
TW201444798A (zh) 2013-02-28 2014-12-01 必治妥美雅史谷比公司 作爲強效ｒｏｃｋ１及ｒｏｃｋ２抑制劑之苯基吡唑衍生物
JP6423372B2 (ja) 2013-02-28 2018-11-14 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 強力なｒｏｃｋ１およびｒｏｃｋ２阻害剤としてのフェニルピラゾール誘導体
JP6434968B2 (ja) 2013-07-02 2018-12-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｒｏｃｋ阻害剤としての三環式ピリド−カルボキサミド誘導体
CN105518005B (zh) 2013-07-02 2018-07-20 百时美施贵宝公司 作为rock抑制剂的三环吡啶-甲酰胺衍生物
US9902702B2 (en) 2014-07-15 2018-02-27 Bristol-Myers Squibb Company Spirocycloheptanes as inhibitors of rock
JP6633618B2 (ja) 2014-08-21 2020-01-22 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 強力なｒｏｃｋ阻害剤としてのタイドバックのベンズアミド誘導体
TW201630899A (zh) 2015-01-09 2016-09-01 必治妥美雅史谷比公司 作為ｒｏｃｋ抑制劑的環狀脲類
ES2730112T3 (es) 2015-03-09 2019-11-08 Bristol Myers Squibb Co Lactamas como inhibidores de ROCK
UY37073A (es) * 2016-01-13 2017-07-31 Bristol-Myers Squibb Company Una Corporación Del Estado De Delaware Salicilamidas espiroheptanos y compuestos relacionados como inhibidores de rock, y las composiciones que los contienen
US10562887B2 (en) 2016-05-27 2020-02-18 Bristol-Myers Squibb Company Triazolones and tetrazolones as inhibitors of ROCK
WO2018009625A1 (en) 2016-07-07 2018-01-11 Bristol-Myers Squibb Company Spirolactams as inhibitors of rock
JP7155102B2 (ja) 2016-07-07 2022-10-18 ブリストル－マイヤーズ スクイブ カンパニー Ｒｏｃｋ阻害剤としてのスピロ縮合環尿素
WO2018009622A1 (en) 2016-07-07 2018-01-11 Bristol-Myers Squibb Company Lactam, cyclic urea and carbamate, and triazolone derivatives as potent and selective rock inhibitors
KR102511441B1 (ko) 2016-11-30 2023-03-16 브리스톨-마이어스 스큅 컴퍼니 트리시클릭 Rho 키나제 억제제

Also Published As

Publication number Publication date
KR102725741B1 (ko) 2024-11-01
EP3954681A1 (en) 2022-02-16
WO2017123860A1 (en) 2017-07-20
TWI730032B (zh) 2021-06-11
ES2898698T3 (es) 2022-03-08
EP3402790A1 (en) 2018-11-21
CL2018001899A1 (es) 2018-11-09
US10829501B2 (en) 2020-11-10
AU2017206820B2 (en) 2021-06-17
CN108699038B (zh) 2021-04-16
JP2022024019A (ja) 2022-02-08
CY1124858T1 (el) 2022-11-25
KR20180097749A (ko) 2018-08-31
PT3402790T (pt) 2021-11-22
AR107354A1 (es) 2018-04-18
IL260448B (en) 2020-09-30
SMT202100660T1 (it) 2022-01-10
JP7268116B2 (ja) 2023-05-02
CN108699038A (zh) 2018-10-23
BR112018013780A2 (pt) 2018-12-11
MX2021005311A (es) 2021-06-23
TW201726619A (zh) 2017-08-01
MA55633A (fr) 2022-02-16
SG11201805927YA (en) 2018-08-30
EP3402790B1 (en) 2021-10-06
EA201891557A1 (ru) 2019-01-31
CA3010900A1 (en) 2017-07-20
PL3402790T3 (pl) 2022-01-24
US10611776B2 (en) 2020-04-07
CO2018008173A2 (es) 2018-08-21
BR112018013780B1 (pt) 2023-12-19
MX382434B (es) 2025-03-13
US20200131200A1 (en) 2020-04-30
AU2021221872A1 (en) 2021-09-23
HRP20211888T1 (hr) 2022-03-04
SI3402790T1 (sl) 2022-01-31
UY37073A (es) 2017-07-31
MX2018008219A (es) 2018-09-07
MA43862A (fr) 2021-06-02
JP2019509978A (ja) 2019-04-11
LT3402790T (lt) 2021-12-10
EA036172B1 (ru) 2020-10-09
AU2017206820A1 (en) 2018-08-23
RS62690B1 (sr) 2021-12-31
US20190016735A1 (en) 2019-01-17
JP6976953B2 (ja) 2021-12-08

Similar Documents

Publication Publication Date Title
HUE057455T2 (hu) Spiroheptán szalicilamidok és rokon vegyületek mint ROCK inhibitorok
IL269196A (en) Novel inhibitors
IL263586A (en) Inhibitors of the menin-mll interaction
DK3497103T3 (da) Pyridopyrimdinon-cdk2/4/6-inhibitorer
HUE057801T2 (hu) Aminotriazolopiridinek mint kináz inhibitorok
HUE064145T2 (hu) Amin-szubsztituált aril- vagy heteroaril vegyületek, mint EHMT1 és EHMT2 inhibitorok
HUE046273T2 (hu) Ciklopropilaminok mint LSD1 inhibitorok
HUE045725T2 (hu) Ciklopropilaminok mint LSD1 inhibitorok
HUE047586T2 (hu) Heteroaril vegyületek mint IRAK inhibitorok és alkalmazásaik
HUE054159T2 (hu) HPK1 gátlók és azok alkalmazási módja
IL280863A (en) Autotaxin inhibitors and uses thereof
DK3888658T3 (da) Eif4-a-inhiberende forbindelser og fremgangsmåder relateret dertil
LT3303334T (lt) Tirozinkinazės inhibitoriai
HUE055755T2 (hu) Szulfonolkarmabidok és rokon vegyületeik valamint felhasználásuk
DK3389658T3 (da) Glycosidasehæmmere og anvendelser deraf
DK3442972T3 (da) Bromdomænehæmmere
LT3319959T (lt) Histono deacetilazės hetero-halogeno inhibitoriai
DK3495023T3 (da) Semifluorerede forbindelser og sammensætninger deraf
DK3571192T3 (da) Jak1-selektive inhibitorer
HUE055233T2 (hu) Az EGFR gátló és annak elkészítése és alkalmazása
HRP20181899T1 (hr) Biaril inhibitori kinaze
HUE050564T2 (hu) Lizinspecifikus demetiláz-1 inhibitorai
HUE054410T2 (hu) 3-tetrazolil-benzol-1,2-diszulfonamid származékok mint fém-béta-laktamáz inhibitorok
HUE061595T2 (hu) Kinazolinonok mint PARP14 inhibitorok
HUE058292T2 (hu) Aminoimidazopiridazinok mint kináz inhibitorok